HER2DX genomic assay in advanced HER2-positive (HER2+) breast cancer treated with T-DM1

被引：0

作者：

Braso-Maristany, F. ^{[1
]}

Griguolo, G. ^{[2
]}

Chic, N. ^{[3
]}

Pare Brunet, L. ^{[3
]}

Galvan, P. ^{[4
]}

Dieci, M. V. ^{[5
]}

Miglietta, F. ^{[6
]}

Giarratano, T. ^{[7
]}

Martinez-Saez, O. ^{[8
]}

Marin, M. ^{[8
]}

Vidal Losada, M. J. ^{[9
]}

Adamo, B. ^{[10
]}

Munoz, M. ^{[11
]}

Vivancos, A. ^{[12
]}

Villagrasa Gonzalez, P. ^{[13
]}

Parker, J. ^{[13
]}

Perou, C. M. ^{[14
]}

Conte, P. F. ^{[15
]}

Prat, A. ^{[16
]}

Guarneri, V. ^{[17
]}

机构：

[1] IDIBAPS Inst Invest Biomed August Pi & Sunyer, Dept Oncol, Barcelona, Spain

[2] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy

[3] Reveal Genom SL, Dept Sci, Barcelona, Spain

[4] IDIBAPS August Pi & Sunyer Biomed Res Inst, Dept Med Oncol, Barcelona, Spain

[5] Univ Padua, DiSCOG, Padua, Italy

[6] IOV Ist Oncol Veneto IRCCS, Dipartimento Oncol, Padua, Italy

[7] IOV Ist Oncologico Veneto IRCCS, Dept Oncol, Padua, Italy

[8] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[9] Hosp Clin Barcelona, Breast Canc, Barcelona, Spain

[10] Hosp Clin Prov Barcelona, Breast Canc Dept, Barcelona, Spain

[11] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[12] Vall Hebron Univ sity Hosp, Genom Dept, Barcelona, Spain

[13] UNC, Dept Oncol, Lineberger Canc Ctr, Chapel Hill, NC USA

[14] UNC, Dept Oncol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[15] IOV Ist Oncol Veneto IRCCS, Surg Oncol & Gastroenterol Dept, Padua, Italy

[16] Hosp Clin Prov Barcelona, Dept Med Oncol, Barcelona, Spain

[17] Univ Padua, Oncol & Gastroenterol Dept, Dept Surg, Padua, Italy

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.276

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

237P

引用

页码：S646 / S646

页数：1

共 50 条

[1] HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1
Braso-Maristany, Fara
Griguolo, Gaia
Chic, Nuria
Pascual, Tomas
Pare, Laia
Maues, Julia
Galvan, Patricia
Dieci, Maria Vittoria
Miglietta, Federica
Giarratano, Tommaso
Martinez-Saez, Olga
Marin-Aguilera, Mercedes
Schettini, Francesco
Conte, Benedetta
Angelats, Laura
Vidal, Maria
Adamo, Barbara
Munoz, Montserrat
Sanfeliu, Esther
Gonzalez, Blanca
Vivancos, Ana
Villagrasa, Patricia
Parker, Joel S.
Perou, Charles M.
Conte, PierFranco
Prat, Aleix
Guarneri, Valentina
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (03): : 332 - 336
[2] RE: HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1
Bertucci, Francois
de Nonneville, Alexandre
Finetti, Pascal
Mamessier, Emilie
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (06): : 762 - 763
[3] Investigating HER2DX genomic assay concordance within HER2-positive breast cancer
Braso-Maristany, Fara
Pare, Laia
Villacampa, Guillermo
Marin-Aguilera, Mercedes
Spellman, Paul
Waks, Adrienne
Krop, Ian
Sanfeliu, Esther
Li, Zhequi
Galvan, Patricia
Hernandez-Illan, Eva
Jares, Pedro
Puig-Butille, Joan Anton
Vivancos, Ana
Villagrasa, Patricia
Parker, Joel S.
Perou, Charles M.
Tolaney, Sara
Metzger, Otto
Polyak, Kornelia
Prat, Aleix
CANCER RESEARCH, 2024, 84 (09)
[4] HER2DX: Advances in targeted treatment of HER2-positive breast cancer
Andujar, Juan M. Cejalvo
REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2024, 37 (03):
[5] Association between tumor infiltrating lymphocytes (TILs) and the HER2DX assay in early-stage of HER2-positive (HER2+) breast cancer
Sanfeliu, Esther
Braso-Maristany, Fara
Dieci, Maria Vittoria
Marin-Aguilera, Mercedes
Gonzalez-Farre, Blanca
Griguolo, Gaia
Pascual, Tomas
Galvan, Patricia
Angelats, Laura
Castillo, Oleguer
Blasco, Paula
Sirenko, Valeria
Jares, Pedro
Puig-Butille, Joan Anton
Pare, Laia
Martinez, Antonio
Llombart-Cussac, Antonio
Cortes, Javier
Vivancos, Ana
Villagrasa, Patricia
Parker, Joel S.
Perou, Charles M.
Prat, Aleix
Conte, PierFranco
Guarneri, Valentina
CANCER RESEARCH, 2023, 83 (05)
[6] T-DM1 for HER2-positive metastatic breast cancer
Yaqub, Farhat
LANCET ONCOLOGY, 2013, 14 (03): : E94 - E94
[7] HER2DX ERBB2 mRNA assay following trastuzumab-based chemotherapy in HER2-positive (HER2+) advanced gastric cancer (AGC)
Sauri Nadal, T.
Pesantez Coronel, D. S.
Braso Maristany, F.
Indacochea, A.
Cuatrecasas, M.
Sanfeliu Torres, E.
Lopezprades, S.
Candia, L.
Fernandez-Esparrach, G.
Mendez, I.
Nogue Aliguer, M.
Momblan, D.
Angelats, L.
Pascual, T.
Prat, A.
ANNALS OF ONCOLOGY, 2024, 35 : S194 - S194
[8] Trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer
Thibault, C.
ONCOLOGIE, 2013, 15 (02) : 126 - 127
[9] Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer
Marin-Aguilera, M.
Jares, P.
Sanfeliu, E.
Villacampa, G.
Hernandez-lllan, E.
Martinez-Puchol, A. I.
Shankar, S.
Gonzalez-Farre, B.
Waks, A. G.
Braso-Maristany, F.
Pardo, F.
Manning, D. K.
Abery, J. A.
Curaba, J.
Moon, L.
Gordon, O.
Galvan, P.
Wachirakantapong, P.
Castillo, O.
Nee, C. M.
Blasco, P.
Senevirathne, T. H.
Sirenko, V.
Martinez-Saez, O.
Aguirre, A.
Krop, I. E.
Li, Z.
Spellman, P.
Metzger Filho, O.
Polyak, K.
Michaels, P.
Puig-Butille, J. A.
Vivancos, A.
Matito, J.
Buckingham, W.
Perou, C. M.
Villagrasa-Gonzalez, P.
Prat, A.
Parker, J. S.
Pare, L.
ESMO OPEN, 2024, 9 (03)
[10] mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Casadevall, David
Hernandez-Prat, Anna
Garcia-Alonso, Sara
Arpi-Llucia, Oriol
Menendez, Silvia
Qin, Mengjuan
Guardia, Cristina
Morancho, Beatriz
Sanchez-Martin, Francisco Javier
Zazo, Sandra
Gavilan, Elena
Sabbaghi, Mohammad A.
Eroles, Pilar
Cejalvo, Juan Miguel
Lluch, Ana
Rojo, Federico
Pandiella, Atanasio
Rovia, Ana
Anabell, Joan
MOLECULAR CANCER RESEARCH, 2022, 20 (07) : 1108 - 1121

← 1 2 3 4 5 →